Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  K. Blennow,et al.  Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia , 2017, Alzheimer's & Dementia.

[3]  Giovanni B. Frisoni,et al.  Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment , 2017, Alzheimer's & Dementia.

[4]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[5]  Jeremy D. Goldhaber-Fiebert,et al.  Some Health States Are Better Than Others , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[7]  Philip Scheltens,et al.  Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges , 2015, Journal of Alzheimer's disease : JAD.

[8]  J. McCarten,et al.  Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. , 2015, Journal of Alzheimer's disease : JAD.

[9]  A. Wimo,et al.  Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment , 2015, Alzheimer's & Dementia.

[10]  V. Pankratz,et al.  Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study , 2015, Alzheimer's & Dementia.

[11]  I. Lombardo,et al.  The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.

[12]  K. Blennow,et al.  The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2014, Alzheimer's & Dementia.

[13]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[14]  P. Lewczuk.  Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment , 2014 .

[15]  D. King,et al.  Scenarios of dementia care: what are the impacts on cost and quality of life? , 2014 .

[16]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[17]  Jennifer H Barnett,et al.  Early intervention in Alzheimer’s disease: a health economic study of the effects of diagnostic timing , 2014, BMC Neurology.

[18]  Olivier Colliot,et al.  Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. , 2014, Biochemical pharmacology.

[19]  Tracy Comans,et al.  MARKOV MODELING AND DISCRETE EVENT SIMULATION IN HEALTH CARE: A SYSTEMATIC COMPARISON , 2014, International Journal of Technology Assessment in Health Care.

[20]  K. Blennow,et al.  The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. , 2013, The Medical clinics of North America.

[21]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[22]  B. Winblad,et al.  Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease--a simulation study. , 2013, Current Alzheimer research.

[23]  Kelly Cho,et al.  Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps , 2012, International journal of Alzheimer's disease.

[24]  K. Siminovitch,et al.  Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment , 2012, Molecular Diagnosis & Therapy.

[25]  Sean D Sullivan,et al.  Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. , 2012, Current Alzheimer research.

[26]  J. Pines,et al.  Cost-effectiveness of diagnostic strategies for evaluation of suspected subarachnoid hemorrhage in the emergency department. , 2012, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[27]  J. Morling,et al.  Cholinesterase inhibitors for mild cognitive impairment. , 2012, The Cochrane database of systematic reviews.

[28]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[29]  Klemen Rojnik,et al.  Handling input correlations in pharmacoeconomic models. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  Laura Temime,et al.  Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer's Disease , 2012, PloS one.

[31]  F. Benedetti,et al.  A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment , 2012, International Psychogeriatrics.

[32]  G. Holt,et al.  Timely Diagnosis and Disclosure of Alzheimer Disease Gives Patients Opportunities to Make Choices , 2011, Southern medical journal.

[33]  P. Lapuerta,et al.  Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: a Markov model simulation , 2011, ClinicoEconomics and outcomes research : CEOR.

[34]  James Shearer,et al.  Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  R. Petersen.  Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[36]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  R. Brookmeyer,et al.  National estimates of the prevalence of Alzheimer’s disease in the United States , 2011, Alzheimer's & Dementia.

[38]  C R Jack,et al.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD , 2010, Neurology.

[39]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[40]  C. Jack,et al.  Serial MRI and CSF biomarkers in normal aging, MCI and Alzheimer's disease , 2010, Alzheimer's & Dementia.

[41]  H. Zetterberg,et al.  To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease , 2010, International journal of Alzheimer's disease.

[42]  Henrik Zetterberg,et al.  Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients , 2010, European Neurology.

[43]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[44]  Timothy M. Klein,et al.  Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model , 2010, BMC Medical Informatics Decis. Mak..

[45]  M G Myriam Hunink,et al.  Uncertainty and Patient Heterogeneity in Medical Decision Models , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  P. Crane.  DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL , 2009, Neurology.

[47]  Dan Mungas,et al.  Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. , 2009, Archives of neurology.

[48]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[49]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[50]  D. Holtzman,et al.  Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. , 2009, CNS & neurological disorders drug targets.

[51]  O. Forlenza,et al.  To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[52]  Andrew H Briggs,et al.  Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[53]  R. Hansen,et al.  Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis , 2008, Clinical interventions in aging.

[54]  Joshua T. Cohen,et al.  Decision analytic models for Alzheimer's disease: State of the art and future directions , 2008, Alzheimer's & Dementia.

[55]  Ron Brookmeyer,et al.  The International Journal of Biostatistics Modeling the Effect of Alzheimer ' s Disease on Mortality , 2011 .

[56]  Nicola Vanacore,et al.  Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.

[57]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[58]  Mark Oppe,et al.  Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[59]  L. Flicker,et al.  Donepezil for mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[60]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[61]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[62]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[63]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[64]  Simon Lovestone,et al.  Is MCI really just early dementia? A systematic review of conversion studies , 2004, International Psychogeriatrics.

[65]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[66]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[67]  K S Kosik,et al.  Measuring Alzheimer’s disease progression with transition probabilities , 2001, Neurology.

[68]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[69]  P J Neumann,et al.  Alzheimer's disease care: costs and potential savings. , 1998, Health affairs.

[70]  D. Feeny,et al.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.

[71]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[72]  A. Wallin,et al.  Low frequency of post‐lumbar puncture headache in demented patients , 1993, Acta neurologica Scandinavica.

[73]  S. Damodaran.  Severity of family distress of schizophrenia—fact or artifact? , 1993, Acta psychiatrica Scandinavica.

[74]  B. McNeil,et al.  Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.

[75]  Jin-Tai Yu,et al.  Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.

[76]  J. Molinuevo,et al.  Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[77]  Carlo Caltagirone,et al.  A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[78]  Denis Getsios,et al.  Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease , 2012, PharmacoEconomics.

[79]  J. Morris,et al.  Cholinesterase Inhibitors for Alzheimer’s Disease , 2012, Drugs.

[80]  P. Visser,et al.  Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.

[81]  I. Kloszewska,et al.  Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. , 2007, Neurologia i neurochirurgia polska.

[82]  Andrew H Briggs,et al.  Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. , 2002, Annual review of public health.

[83]  M. Weinstein,et al.  Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. , 1999, Medical care.